PHILADELPHIA — Survival in idiopathic pulmonary fibrosis (IPF) improved significantly in patients treated with proton pump inhibitors (PPIs), adding to a body of literature supporting PPI benefits in IPF, investigators in a retrospective review concluded.
Patients treated with PPIs had a mean transplant-free survival of 3.4 years compared with 1.4 years in a group of patients who did not receive the drugs. Patients with no history of gastroesophageal reflux (GER) or history of PPI use derived even greater benefit from the antireflux therapy.
Subsequent laboratory studies suggested a mechanism for the benefit, beyond antireflux effects: inhibition of dimethylarginine dimethylaminohydrolase (DDAH), which regulates nitric oxide synthetase in fibroblasts from IPF.
Read the entire article at:
For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com